Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Basic Clin Pharmacol Toxicol ; 121(6): 465-470, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28654209

RESUMO

Using moxifloxacin and terfenadine, which are known to induce benign and malignant QT interval prolongation, respectively, we analysed whether halothane-anaesthetized microminipigs are an appropriate model for assessing the risk of drug-induced long QT syndrome. Moxifloxacin (0.03, 0.3 and 3 mg/kg) and terfenadine (0.03, 0.3 and 3 mg/kg) were intravenously infused over 10 min. with a pause of 20 min. to the halothane-anaesthetized microminipigs (n = 4 for each drug). Moxifloxacin decreased the heart rate, whereas it increased the blood pressure in a dose-related manner. It also prolonged the PR interval and QT/QTc in a dose-related manner without altering the QRS width. Terfenadine decreased the heart rate and blood pressure, whereas it prolonged the PR interval, QRS width and QT/QTc in a dose-related manner. Terfenadine significantly prolonged the beat-to-beat variability of QT interval reflecting its pro-arrhythmic potential, which was not observed with moxifloxacin. The peak plasma concentrations of moxifloxacin and terfenadine after doses of 3 mg/kg were 4.81 and 10.15 µg/mL, respectively, which were both 1.5 times less in microminipigs than those previously reported in dogs. These results indicate that halothane-anaesthetized microminipigs would be useful for detecting drug-induced cardiovascular responses as well as differentiating benign from malignant QT interval prolongation like dogs, although there may be some differences in pharmacokinetic profile between these animals.


Assuntos
Anestésicos Inalatórios/farmacologia , Halotano/farmacologia , Síndrome do QT Longo/induzido quimicamente , Animais , Arritmias Cardíacas/induzido quimicamente , Pressão Sanguínea/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Fluoroquinolonas/efeitos adversos , Fluoroquinolonas/sangue , Fluoroquinolonas/farmacocinética , Frequência Cardíaca , Síndrome do QT Longo/epidemiologia , Masculino , Moxifloxacina , Reprodutibilidade dos Testes , Medição de Risco , Sensibilidade e Especificidade , Suínos , Porco Miniatura , Terfenadina/efeitos adversos , Terfenadina/sangue , Terfenadina/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA